• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

Shares of Gilead Could Surge to the $88 Area in the Near-Term

Any modest intraday dip is probably a buying opportunity.
By BRUCE KAMICH
Feb 24, 2020 | 09:17 AM EST
Stocks quotes in this article: GILD, SFOSF

Gilead Sciences (GILD) is the 'Stock of the Day' at Real Money on Monday. 

According to published reports, Fosun Kite Biotechnology has said in an exchange filing that an application for a cancer treatment was accepted by China's National Medical Products Administration. The company is a joint venture between Gilead Sciences' Kite Pharma and Shanghai Fosun Pharmaceutical (SFOSF) . (Also of interest to investors are the Wuhan-based clinical trials evaluating Gilead's antiviral drug remdesivir for the potential treatment of the SARS-CoV-2 infection which are proceeding slowly due to the lack of qualified participants.) All of this is well above my pay grade so let's look at the charts of GILD.  

In this daily bar chart of GILD, below, we can see that prices largely traded sideways the past 12 months. GILD went up and down in about a $10 range from the $61 area on the downside to the $70-$71 area on the upside. Prices crossed above and below the popular 50-day and 200-day moving average lines several times but they are now above both averages which have positive slopes.

The daily On-Balance-Volume (OBV) line shows a rising pattern the past 12 months. Buyers of GILD have been more aggressive in the past year even as prices moved sideways. Underneath the neutral price action, accumulation can be seen - investors with foresight have been buyers.

The trend-following Moving Average Convergence Divergence (MACD) oscillator crossed above the zero line in early February and is pointed upwards in a bullish configuration.  

In this weekly bar chart of GILD, below, we can see the price action of the past three years. Since December 2018 we can see that prices have made a base. The 40-week moving average line has bottomed.

The weekly OBV line shows a rise from December of 2018 and more recently a dramatic move to the upside.

The MACD oscillator made several cover shorts buy signals the past year before crossing the zero line this month for a buy signal.  

In this daily Point and Figure chart of GILD, below, we can see a potential upside price target in the $78 area. With prices trading around $73 earlier in the pre-market a weekly perspective would help.  

In this weekly Point and Figure chart of GILD, below, a potential upside price target of $88 is being projected.  

Bottom line strategy: GILD is likely to start the day higher. Any modest intraday dip is probably a buying opportunity. New and existing longs should raise sell stops to a close below $66 for now.  $78 and $88 are our price targets for now.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Drug Approvals | Investing | Markets | Stocks | Technical Analysis | Trading | Pharmaceuticals | China | Stock of the Day

More from Investing

I'm Making Small Bets With These 2 Stocks

Bret Jensen
Jan 27, 2023 11:30 AM EST

While I remain cautious on the overall market, I continue to act upon the limited opportunities I'm finding in the current market.

Chevron Is Crushing It and for My Portfolio Too: Here's the Trade

Stephen Guilfoyle
Jan 27, 2023 10:51 AM EST

The only reason to exit the stock now is profit-taking.

Good Dividend Payers With Pretty Charts

Bruce Kamich
Jan 27, 2023 10:15 AM EST

You can have the best of both worlds -- at least when it comes to a select group of dividend stocks -- as we'll see in this first part of a two part series.

Adani Companies Plunge Under Hindenburg Attack, Hurting Secondary Sale Attempt

Alex Frew McMillan
Jan 27, 2023 9:30 AM EST

Retail investors may baulk now they are being offered Adani Enterprises shares at a range well above their current trading price.

Intel Tanks (Again), but I Spy 3 Other Charts That Look Pretty Darn Good

Bob Byrne
Jan 27, 2023 9:00 AM EST

The trio consists of a beverage seller, a connectivity company and a producer of advanced driving system technology.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:48 AM EST REAL MONEY

    Watch Doug Kass on the Daily Rundown!

    In today's Action Alerts PLUS Daily Rundown, Doug ...
  • 11:03 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend On Real Money

    It's time to start using this power to build great...
  • 03:06 PM EST BOB LANG

    LEAPS Webinar

    This week, I offered a free webinar session talkin...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login